Total Payments
$17,690
2024 Payments
$1,784
Companies
39
Transactions
465
Medicare Patients
5,853
Medicare Billing
$618,412
Payment Breakdown by Category
Food & Beverage$15,743 (89.0%)
Research$1,573 (8.9%)
Education$336.93 (1.9%)
Travel$36.94 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,743 | 448 | 89.0% |
| Unspecified | $1,573 | 10 | 8.9% |
| Education | $336.93 | 5 | 1.9% |
| Travel and Lodging | $36.94 | 2 | 0.2% |
Payments by Type
General
$16,117
455 transactions
Research
$1,573
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $1,744 | 12 | $0 (2019) |
| PFIZER INC. | $1,666 | 100 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,186 | 23 | $0 (2024) |
| GENZYME CORPORATION | $1,042 | 23 | $0 (2024) |
| Galderma Laboratories, L.P. | $1,037 | 28 | $0 (2020) |
| Janssen Biotech, Inc. | $956.38 | 39 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $892.72 | 13 | $0 (2021) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $677.08 | 20 | $0 (2023) |
| ABBVIE INC. | $656.41 | 19 | $0 (2024) |
| Dermavant Sciences, Inc. | $607.86 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,784 | 31 | E.R. Squibb & Sons, L.L.C. ($394.59) |
| 2023 | $1,617 | 29 | E.R. Squibb & Sons, L.L.C. ($673.26) |
| 2022 | $1,466 | 24 | GENZYME CORPORATION ($284.73) |
| 2021 | $991.96 | 31 | SUN PHARMACEUTICAL INDUSTRIES INC. ($333.66) |
| 2020 | $842.94 | 30 | Galderma Laboratories, L.P. ($167.52) |
| 2019 | $4,839 | 98 | Regeneron Pharmaceuticals, Inc. ($1,744) |
| 2018 | $3,232 | 89 | SANOFI-AVENTIS U.S. LLC ($481.01) |
| 2017 | $2,917 | 133 | PFIZER INC. ($364.14) |
All Payment Transactions
465 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $6.14 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $127.23 | General |
| Category: Immunology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $8.74 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $12.35 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $108.04 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $59.73 | General |
| Category: Dermatology | ||||||
| 10/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $11.45 | General |
| Category: Immunology | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 09/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Immunology | ||||||
| 09/03/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.97 | General |
| Category: Immunology | ||||||
| 08/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $89.03 | General |
| Category: Immunology | ||||||
| 08/15/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: Immunology | ||||||
| 07/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: IMMUNOLOGY | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $7.22 | General |
| Category: Immunology | ||||||
| 05/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $121.36 | General |
| Category: Immunology | ||||||
| 05/16/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $31.94 | General |
| Category: Immunology | ||||||
| 05/14/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $13.08 | General |
| Category: Immunology | ||||||
| 04/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: Immunology | ||||||
| 04/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: Immunology | ||||||
| 04/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $36.70 | General |
| Category: Immunology | ||||||
| 04/02/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $7.29 | General |
| Category: Immunology | ||||||
| 03/28/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: DERMATOLOGY | ||||||
| 03/28/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $6.82 | General |
| Category: DERMATOLOGY | ||||||
| 03/10/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $154.64 | General |
| Category: DERMATOLOGY | ||||||
| 03/08/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $181.85 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,573 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,142 | 3,551 | $206,739 | $133,166 |
| 2022 | 15 | 1,082 | 3,116 | $197,480 | $123,722 |
| 2021 | 13 | 1,074 | 3,166 | $191,343 | $126,562 |
| 2020 | 20 | 2,555 | 6,896 | $364,384 | $234,962 |
Total Patients
5,853
Total Services
16,729
Medicare Billing
$618,412
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 291 | 661 | $68,733 | $44,140 | 64.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 91 | 140 | $28,355 | $19,796 | 69.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 199 | 332 | $26,622 | $15,533 | 58.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 182 | 1,929 | $15,859 | $11,300 | 71.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 104 | 129 | $15,930 | $10,345 | 64.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 70 | 91 | $12,569 | $7,989 | 63.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 67 | 117 | $9,925 | $7,542 | 76.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 23 | 26 | $9,597 | $6,455 | 67.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 52 | 52 | $6,634 | $3,636 | 54.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 29 | $4,293 | $2,764 | 64.4% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 15 | 20 | $6,712 | $2,511 | 37.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 21 | 25 | $1,509 | $1,154 | 76.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 275 | 635 | $67,067 | $40,929 | 61.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 77 | 127 | $25,688 | $18,020 | 70.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 187 | 301 | $24,356 | $13,362 | 54.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 80 | 108 | $15,010 | $10,208 | 68.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 98 | 117 | $14,856 | $9,194 | 61.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 155 | 1,577 | $13,184 | $9,185 | 69.7% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2022 | 23 | 27 | $9,830 | $7,148 | 72.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 68 | 98 | $8,321 | $6,294 | 75.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 43 | 43 | $5,512 | $2,994 | 54.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2022 | 13 | 14 | $4,607 | $1,773 | 38.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 13 | 14 | $4,074 | $1,557 | 38.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 12 | $1,766 | $902.20 | 51.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 14 | 16 | $1,048 | $802.76 | 76.6% |
About Dr. Ruth Gilboa, MD
Dr. Ruth Gilboa, MD is a Dermatology healthcare provider based in Solana Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205873197.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruth Gilboa, MD has received a total of $17,690 in payments from pharmaceutical and medical device companies, with $1,784 received in 2024. These payments were reported across 465 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($15,743).
As a Medicare-enrolled provider, Gilboa has provided services to 5,853 Medicare beneficiaries, totaling 16,729 services with total Medicare billing of $618,412. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Solana Beach, CA
- Active Since 06/01/2006
- Last Updated 02/10/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1205873197
Products in Payments
- EUCRISA (Drug) $1,140
- Sotyktu (Drug) $1,068
- DUPIXENT (Biological) $1,055
- DUPIXENT (Drug) $990.92
- VTAMA (Drug) $607.86
- Tremfya (Drug) $601.53
- EPIDUO FORTE (Drug) $556.42
- COSENTYX (Biological) $429.51
- Enbrel (Biological) $363.99
- CIBINQO (Drug) $346.58
- TREMFYA (Drug) $340.45
- DUPIXENT DUPILUMAB INJECTION (Biological) $326.59
- Bimzelx (Biological) $310.07
- SOOLANTRA (Drug) $308.05
- Humira (Biological) $305.68
- QBREXZA (Drug) $296.03
- ENSTILAR (Drug) $291.53
- GUSELKUMAB (Biological) $284.19
- OPZELURA (Drug) $279.19
- Cordran (Drug) $251.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.